Morphosys Reports Decreased Losses in Q2

1 Mins read

By Andrea Figueras

Morphosys, the German biopharmaceutical company, announced improved financial performance in the second quarter of the year. Despite a decline in revenue, lower costs helped narrow net and operating losses.

Strong Improvement in Financials

Morphosys reported a significant decrease in net loss for Q2, reducing it to 74 million euros ($81.2 million) compared to the previous year’s loss of EUR235 million. The company also saw a reduction in operating loss, with figures dropping from EUR55.1 million to EUR50.5 million.

Revenue Decline Offset by Cost Reductions

Although revenue dipped by 10% to EUR53.2 million, Morphosys successfully mitigated the impact through cost-cutting measures. The quarterly sales of Monjuvi, the company’s main product which treats lymphoma, remained stable at EUR21.7 million.

Positive Outlook for Monjuvi

Morphosys maintains a positive outlook for Monjuvi, anticipating net product sales in the U.S. to range between $80 million and $95 million for the year. The company expects a gross margin of 75% to 80% for Monjuvi and estimates research-and-development expenses to be between EUR290 million and EUR315 million.

Related posts

Banking Regulations for Preventing Failures

2 Mins read
Banking regulators have the power to prevent future bank collapses, according to a panel of banking experts who emphasized the importance of…

Dave's Strong Q4 Performance

1 Mins read
Shares of Dave surged on Tuesday following the digital bank’s announcement of a profitable fourth quarter earlier than expected, with a positive…

DaVita Expands in Latin America

1 Mins read
Shares of DaVita reached record levels as the kidney care services company announced its significant expansion into Latin America through a $300…

Leave a Reply

Your email address will not be published. Required fields are marked *

89 + = 91